HM
PCRX icon

HealthCor Management’s Pacira BioSciences PCRX Stock Holding History

HealthCor Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,930
Closed -$1.06M – 69
2022
Q1 		$1.06M Buy
+13,930
New +$929K 0.07% 57
2020
Q3 		– Sell
-405,040
Closed -$21.3M – 55
2020
Q2 		$21.3M Sell
405,040
-482,330
-54% -$20.2M 0.89% 33
2020
Q1 		$29.8M Buy
887,370
+116,230
+15% +$4.83M 1.27% 26
2019
Q4 		$34.9M Buy
+771,140
New +$32.8M 1.25% 32
2019
Q2 		– Sell
-706,379
Closed -$26.9M – 63
2019
Q1 		$26.9M Sell
706,379
-1,791,749
-72% -$69.9M 1.09% 33
2018
Q4 		$107M Buy
2,498,128
+552,588
+28% +$25.8M 3.36% 13
2018
Q3 		$95.6M Sell
1,945,540
-909,673
-32% -$39.3M 3.17% 12
2018
Q2 		$91.5M Buy
2,855,213
+555,213
+24% +$19.2M 2.91% 11
2018
Q1 		$71.6M Sell
2,300,000
-500,000
-18% -$17.8M 2.44% 11
2017
Q4 		$128M Buy
2,800,000
+221,960
+9% +$8.8M 4.16% 9
2017
Q3 		$96.8M Buy
2,578,040
+784,241
+44% +$31.6M 3.24% 10
2017
Q2 		$85.6M Buy
1,793,799
+693,799
+63% +$32.2M 3.09% 10
2017
Q1 		$50.2M Sell
1,100,000
-475,000
-30% -$20.5M 2.3% 15
2016
Q4 		$50.9M Buy
1,575,000
+830,720
+112% +$27.7M 2.87% 15
2016
Q3 		$25.5M Buy
744,280
+494,280
+198% +$19.4M 1.55% 22
2016
Q2 		$8.43M Buy
+250,000
New +$12.3M 0.46% 37
2016
Q1 		– Sell
-21,500
Closed -$1.65M – 48
2015
Q4 		$1.65M Buy
+21,500
New +$1.22M 0.1% 37
2015
Q1 		– Sell
-125,000
Closed -$11.1M – 73
2014
Q4 		$11.1M Buy
+125,000
New +$11.8M 0.62% 36

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

HealthCor Management's PCRX Position: Q2 2022 in Review

HealthCor Management sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 13,930 shares — an estimated $1.06M sold.

HealthCor Management first reported a position in PCRX in Q4 2014 and held it in 18 quarters. The position peaked at $128M in Q4 2017. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

  • HealthCor Management reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
  • HealthCor Management sold 13,930 Pacira BioSciences shares in Q2 2022, an estimated $1.06M.
  • HealthCor Management first reported a position in Pacira BioSciences in Q4 2014 and held it in 18 quarters.
  • HealthCor Management's Pacira BioSciences position peaked at $128M in Q4 2017.
  • 284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on HealthCor Management's 13F filing for Q2 2022, filed 15 Aug 2022.